Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERACT: Fulvestrant vs AI with CDK4/6i in ESR1-mutated Breast Cancer
NCT04256941Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fulvestrant in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Started May 2019; status: terminated.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04256941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04256941.